Therapix Biosciences Ltd. (TRPX) SEC Filing 6-K Foreign Issuer report for the period ending Friday, July 5, 2019

Therapix Biosciences Ltd.

CIK: 1611746 Ticker: TRPX

View differences made from one to another to evaluate Therapix Biosciences Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Therapix Biosciences Ltd..


Assess how Therapix Biosciences Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Therapix Biosciences Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Therapix Biosciences Ltd. provided additional information to their SEC Filing as exhibits

Ticker: TRPX
CIK: 1611746
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001213900-19-012109
Submitted to the SEC: Fri Jul 05 2019 6:08:49 AM EST
Accepted by the SEC: Fri Jul 05 2019
Period: Friday, July 5, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: